Overview

Incepted in December 2012, Medeon Biodesign, an incubator group with focus on developing high value and high impact medical device products, is founded by the serial entrepreneur, Dr. Yue-Teh Jang, along with two prestigious healthcare institutional investors, Center Laboratories (TSE ticker: 4123), and Taiwan Global BioFund of YFY Group (TSE ticker: 1907). With headquarters based in Taipei, Taiwan and a US subsidiary located in Los Altos, California, together we bring in the integrated elements of skillful medical professionals, talented engineers, and international infrastructure, as the serving grounds for the innovative medtech platform we believe would thrive and shine.

The Company is devoted to the development of devices for minimally invasive surgeries, and the areas of interest are treating diseases of sizable patient population, such as cardiovascular, peripheral vascular, orthopedic, neurosurgery, obesity, gastroenterology, hematology, nephrology, gynecology, urology, and plastic surgery. We focus on products that provide immediate relief for patient symptoms and discomfort, meanwhile, to equip physicians with effective and ease-of-use tools in the result of reducing procedure time as well as lowering the overall medical cost, which would ultimately benefit the patients, medical professionals and healthcare organizations.

Communal collaboration with either entrepreneurs or physicians along the course of product development cycle is extremely essential to our success, and we welcome any kind of creative models for project initiation, and strongly believe the rewards and risks could be shared with partners in a fair and transparent manner.

Our unique strength stands on the methodology and extensive experiences in taking a project from concept shaping to commercialization of products which includes the early product design, prototyping, bench study, animal testing, and conducting first-in-man clinical trial. After successful proof of product efficacy and safety in human clinical trial, financial returns will be diligently pursued through partnership with major industry players to gain regulatory approval and market the products in main territories. We believe diversified and quality partnerships are critical for the continuous growth of the Company to nourish the birth of innovative products which would beneficially influence the physician practices and ultimately address those important unmet medical needs.